Qiagen NV
http://www.qiagen.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Qiagen NV
Top 100 Outlook 2021: Medtechs Look To Build On Experiences Of Serving Global Markets In A Pandemic
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
TScan Teams Up With Qiagen On T Cell COVID-19 Test
A new deal gives Qiagen the option to license T cell-based COVID-19 tests based on the T cell receptor targets identified with TScan’s technology.
Dealmaking: Q3 Roundup Shows Deal Values Jump From Prior Quarter
Device company M&A values reached $17.9bn in Q3, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Company Information
- Industry
- Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Amnisure International LLC
- Biobase, Biotage
- Corbett Life Science Pty. Ltd.
- Digene Corporation
- DxS
- eGene, Inc.
- ESE GmbH
- Exiqon
- Ingenuity Systems Inc
- Genaco Biomedical Products, Inc.
- MAQGEN
- MO BIO Laboratories
- NeuMoDx Molecular, Inc.
- OmicSoft Corporation
- SABiosciences Corporation
- Ipsogen S.A.
- Qiagen Manchester Limited
- Qiagen N.V.
- Xeragon Inc.